-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $40

Benzinga·11/19/2025 10:19:05
Listen to the news
BTIG analyst Kambiz Yazdi initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $40.